Vanguard Group
ALXO icon

Vanguard Group’s ALX Oncology ALXO Stock Holding History

Vanguard Group’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.84M Buy
1,630,940
+102,321
+7% +$155K ﹤0.01% 3581
2025
Q3 		$2.8M Sell
1,528,619
-72,189
-5% -$62.5K ﹤0.01% 3467
2025
Q2 		$664K Sell
1,600,808
-237,115
-13% -$120K ﹤0.01% 3860
2025
Q1 		$1.15M Sell
1,837,923
-49,079
-3% -$58.9K ﹤0.01% 3672
2024
Q4 		$3.15M Buy
1,887,002
+2,429
+0.1% +$3.73K ﹤0.01% 3433
2024
Q3 		$3.43M Buy
1,884,573
+157,325
+9% +$585K ﹤0.01% 3400
2024
Q2 		$10.4M Buy
1,727,248
+160,784
+10% +$1.98M ﹤0.01% 2893
2024
Q1 		$17.5M Buy
1,566,464
+64,055
+4% +$900K ﹤0.01% 2672
2023
Q4 		$22.4M Buy
1,502,409
+494,173
+49% +$4.69M ﹤0.01% 2544
2023
Q3 		$4.84M Buy
1,008,236
+1,648
+0.2% +$8.94K ﹤0.01% 3262
2023
Q2 		$7.56M Sell
1,006,588
-28,951
-3% -$190K ﹤0.01% 3108
2023
Q1 		$4.68M Sell
1,035,539
-389,759
-27% -$2.95M ﹤0.01% 3339
2022
Q4 		$16.1M Buy
1,425,298
+14,289
+1% +$160K ﹤0.01% 2730
2022
Q3 		$13.5M Buy
1,411,009
+86,272
+7% +$1.01M ﹤0.01% 2809
2022
Q2 		$10.7M Sell
1,324,737
-350,919
-21% -$3.82M ﹤0.01% 2954
2022
Q1 		$28.3M Sell
1,675,656
-32,378
-2% -$553K ﹤0.01% 2591
2021
Q4 		$36.7M Buy
1,708,034
+28,506
+2% +$1.23M ﹤0.01% 2522
2021
Q3 		$124M Buy
1,679,528
+129,810
+8% +$8.65M ﹤0.01% 1863
2021
Q2 		$84.7M Buy
1,549,718
+192,610
+14% +$11.5M ﹤0.01% 2081
2021
Q1 		$100M Buy
1,357,108
+473,846
+54% +$37.3M ﹤0.01% 1946
2020
Q4 		$76.1M Buy
883,262
+237,880
+37% +$14.3M ﹤0.01% 1974
2020
Q3 		$24.4M Buy
+645,382
New +$25.4M ﹤0.01% 2357

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group's ALXO Position: Q4 2025 in Review

Vanguard Group increased its ALX Oncology (ALXO) stake by 6.7% in Q4 2025, buying an estimated $155K and bringing the position to 1,630,940 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3581.

Vanguard Group first reported a position in ALXO in Q3 2020 and has held it in 22 quarters since. The position peaked at $124M in Q3 2021. 57 funds tracked by Wall St. Rank hold ALXO as of Q4 2025.

  • Vanguard Group held 1,630,940 shares of ALX Oncology worth $1.84M as of Q4 2025.
  • Vanguard Group bought 102,321 ALX Oncology shares in Q4 2025, an estimated $155K.
  • ALX Oncology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3581 holding.
  • Vanguard Group first reported a position in ALX Oncology in Q3 2020 and has held it in 22 quarters since.
  • Vanguard Group's ALX Oncology position peaked at $124M in Q3 2021.
  • 57 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.